EUVIMEDEUVIMED entdecken
Systematische Übersicht

Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review

Helen Michaela de Oliveira iD, Mariano Gallo Ruelas, Pandora Eloa Oliveira Fonseca, Camilo André Viana Diaz, Guilherme Oliveira de Paula, Pablo Ramon Fruett da Costa, Tariq Parker, Kristopher T Kahle

Headache: The Journal of Head and Face Pain · 2026-01 · 66 (1) · 286-297

DOI: 10.1111/head.70005 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 17.11.2025. Verfasst von Helen Michaela de Oliveira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Federal University of Mato Grosso, Sinop, Brazil. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pseudotumor Cerebri. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NINDS NIH HHS, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study summarizes the evidence on the clinical effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in adults with idiopathic intracranial hypertension (IIH).

Background

IIH is characterized by elevated intracranial pressure with normal neuroimaging and cerebrospinal fluid composition. Standard therapies (e.g., acetazolamide, topiramate) provide modest benefit and are often poorly tolerated. GLP‐1 RAs, which induce weight loss and have been shown experimentally to reduce cerebrospinal‐fluid secretion, are emerging as potential adjuncts, but clinical evidence has not been synthesized comprehensively.

Methods

PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov , and the World Health Organization‐International Clinical Trials Registry Platform were searched from inception to July 2025. Human studies evaluating any GLP‐1RA in IIH were eligible. Two reviewers independently screened records, extracted data, and appraised risk of bias (Risk Of Bias in Randomized Studies tool for randomized trials, Risk Of Bias In Nonrandomized Studies—of Interventions tool and Risk Of Bias In Nonrandomized Studies—of Exposures for observational cohorts, Joanna Briggs Institute for case reports). Heterogeneity and overlapping cohorts precluded meta‐analysis; findings were synthesized narratively. The protocol was registered in International Prospective Register of Systematic Reviews (CRD420251058602).

Results

Twelve reports met criteria: three randomized controlled trials, six retrospective cohorts, one case–control study, and two case reports. Across these studies, GLP‐1RA treatment generally aligned with improvements in papilledema, headache burden, and body mass index, whereas visual outcomes and intracranial pressure data were more variable. The database cohorts suggested a consistent benefit, whereas findings in prospectively followed patients were mixed. Reported adverse effects were mostly mild gastrointestinal symptoms; some cohorts noted reduced reliance on acetazolamide and no cognitive decline. Evidence certainty was low because of observational designs, short follow‐up, and nonstandardized outcome definitions.

Conclusion

Low‐certainty evidence suggests GLP‐1 RAs may reduce papilledema, headache burden, and body weight in IIH without apparent cognitive harm, but findings are inconsistent and driven largely by database analyses and small trials. Larger, well‐powered randomized studies with uniform ophthalmic and headache endpoints, quality‐of‐life measures, and dose–response evaluation are needed to confirm efficacy and define long‐term safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsPseudotumor CerebriHumans

Stichwörter der Autor:innen

exenatideidiopathic intracranial hypertensionliraglutidesemaglutidetirzepatide

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, Federal University of Mato Grosso, Sinop, Brazil.
  • Instituto de Investigación Nutricional (IIN), Lima, Peru.
  • Department of Medicine, Federal University of Campina Grande, Campina Grande, Brazil.
  • Department of Medicine, Federal University of Triângulo Mineiro, Uberaba, Brazil.
  • Department of Functional Neurosurgery, Sinedor Clinic, Sinop, Brazil.
  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Helen Michaela de Oliveira

Förderung

  • NINDS NIH HHS
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

de Oliveira, H. M., Gallo Ruelas, M., Fonseca, P. E. O., Diaz, C. A. V., de Paula, G. O., da Costa, P. R. F., Parker, T., & Kahle, K. T. (2026). Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review. Headache: The Journal of Head and Face Pain, 66(1), 286-297. https://doi.org/10.1111/head.70005

Vancouver

de Oliveira HM, Gallo Ruelas M, Fonseca PEO, Diaz CAV, de Paula GO, da Costa PRF, et al. Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review. Headache: The Journal of Head and Face Pain. 2026;66(1):286-297. doi:10.1111/head.70005

BibTeX
@article{deOliveira2026,
  author = {de Oliveira, Helen Michaela and Gallo Ruelas, Mariano and Fonseca, Pandora Eloa Oliveira and Diaz, Camilo André Viana and de Paula, Guilherme Oliveira and da Costa, Pablo Ramon Fruett and Parker, Tariq and Kahle, Kristopher T},
  title = {Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {1},
  pages = {286--297},
  doi = {10.1111/head.70005}
}
Kostenlos starten →